NAVA use in preterm neonates with respiratory distress syndrome
Official title: Neurally Adjusted Ventilatory Assist [NAVA] Versus Conventional Ventilation in Preterm Neonates With Respiratory Distress Syndrome
Run by Ain Shams University · NCT07926009 · Data updated 2026-11-12
This trial tests whether neurally adjusted ventilatory assist (NAVA) helps preterm babies with respiratory distress syndrome breathe more easily than conventional ventilation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 1 Day to 1 Month |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo, Abbasia) |
| Status | Recruiting |
| Started | January 24, 2026 |
| Main results expected | October 2027 |
| Study ends | January 2028 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07926009 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Preterm neonates ≤34 weeks gestation with radiologically confirmed RDS who require invasive mechanical ventilation.
✕Probably not a fit
Neonates with respiratory distress from causes other than RDS, central or peripheral drive limitations, diaphragmatic anatomical defects, or certain cardiac conditions may not benefit from NAVA.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial compares neurally adjusted ventilatory assist (NAVA) to conventional SIMV ventilation in preterm neonates with respiratory distress syndrome who require invasive ventilation. NAVA uses the diaphragm's electrical activity to guide breaths, aiming to improve synchrony between patient effort and ventilator support. Improved synchrony can reduce work of breathing, lower peak airway pressures, and potentially enhance oxygenation while minimizing lung injury. Ventilation is delivered using Maquet Servo-n, Drager, or SLE ventilators, and eligible participants are ≤34 weeks gestation with RDS confirmed clinically and radiologically. The study will enroll neonates admitted to NICUs at Ain Shams University and follow standard safety monitoring and outcome assessments.
Why it matters
Potential benefit: If successful, NAVA could improve breathing efficiency and reduce lung injury risk in preterm infants requiring invasive ventilation.
How similar studies have gone: Previous evidence suggests improved synchrony and respiratory parameters with NAVA in preterm infants, supporting exploration in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Gestational age ≤ 34 weeks.
2. Neonates that have RDS according to clinical and radiological findings
3. Neonates requiring invasive mechanical ventilation.
Exclusion Criteria:
* 1\) Preterm neonates that have respiratory distress due to causes other than respiratory distress syndrome including transient tachypnea of new born , congenital pneumonia and sepsis. 2)Central and peripheral conditions that limit the respiratory drive, as well as diaphragmatic anatomical defects in patients with an intact respiratory drive, comprise the contraindications to NAVA
* Examples are the following:
* Central disorder: paralytic drug use, respiratory drive suppression due to heavy sedation or brain injury.
* Peripheral disorder: phrenic nerve injury, paralytic agent administration.
* Structural (anatomical) disorder: esophageal atresia, diaphragmatic hernia. 3) Cardiac patients including aortic coarctation , double outlet right ventricle (DORV), Tetralogy of Fallot and Transposition of the great arteries (TGA). 4) Surgical patients including gastroschisis , omphalocele , tracheoesophageal fistula and congenital diaphragmatic hernia (CDH).
Where it's running
-
Neonatal Intensive Care Units (NICUs), Ain Shams University
Cairo, Abbasia, Egypt Recruiting
Study contacts
- Study coordinator: Rania Ali El-Farrash
- Phone: +201222208550
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Left DLPFC rTMS vs iTBS for emotional dysregulation, impulsivity, and NSSI in Borderline Personality Disorder
This trial tests whether high-frequency rTMS or intermittent theta-burst stimulation over the left DLPFC can help reduce emotional instability, impulsivity, and non-suicidal self-injury in adults with Borderline Personality Disorder.
-
Trimetazidine as an extra therapy for aluminum phosphide poisoning
In this pilot trial, adults with acute aluminum phosphide poisoning receive standard care plus trimetazidine to see if it helps save lives and improve recovery.
-
Comparing 3D Face Scans with Manual Measurements for Vertical Dimension in People with Complete Dentures
This study tests whether a 3D face scan can reliably measure the vertical dimension of occlusion in people who wear complete dentures, compared with traditional manual methods.
-
Pre-adapted 3D-printed, patient-specific mesh for unilateral orbital fractures with or without navigation
This study tests whether pre-bending an in-stock titanium mesh using a patient’s 3D-printed skull model improves repair outcomes for unilateral orbital fractures compared with conventional free-hand bending and with navigation-assisted placement.
-
Papillary vs non-papillary access during PCNL
This trial tests whether non-papillary renal access is a safe and effective alternative to the standard papillary approach during percutaneous nephrolithotomy in adults with kidney stones.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.